INTRODUCTION: Burkholderia cepacia infection has been associated with a poor prognosis for patients with cystic fibrosis (CF). It is now recognised that organisms classified as B cepacia comprise a number of distinct genomic species each known as a genomovar of the B cepacia complex (BCC). The outcome of infection for CF patients with individual genomovars is unknown. The clinical outcome of infection with the two most commonly isolated genomovars (B cenocepacia and B multivorans) was studied at a specialist CF centre between 1982 and 2003. METHODS: The numbers of patients who progressed from initial to chronic infection were assessed. Control groups were created by matching patients with chronic BCC infection by percentage forced expiratory volume in 1 second with patients with Pseudomonas aeruginosa infection. Outcome measures were survival time, deaths from "cepacia syndrome", rate of decline in spirometry and body mass index (BMI), and treatment requirements. RESULTS: Forty nine patients had an initial infection with either B multivorans (n = 16) or B cenocepacia (n = 33); 8/16 and 31/33, respectively, developed chronic infection (p<0.001). Deaths from "cepacia syndrome" occurred in both BCC groups. Patients with B cenocepacia infection had a shorter survival than patients with P aeruginosa infection (p = 0.01). There was no difference in survival between CF patients infected with B multivorans and P aeruginosa. There were no observed differences in changes in spirometry and BMI or treatment requirements between the BCC groups and respective controls. CONCLUSION: In CF, the genomovar status of BCC may influence both the likelihood of progression from initial to chronic infection and the overall survival of the patients.
INTRODUCTION:Burkholderia cepacia infection has been associated with a poor prognosis for patients with cystic fibrosis (CF). It is now recognised that organisms classified as B cepacia comprise a number of distinct genomic species each known as a genomovar of the B cepacia complex (BCC). The outcome of infection for CF patients with individual genomovars is unknown. The clinical outcome of infection with the two most commonly isolated genomovars (B cenocepacia and B multivorans) was studied at a specialist CF centre between 1982 and 2003. METHODS: The numbers of patients who progressed from initial to chronic infection were assessed. Control groups were created by matching patients with chronic BCC infection by percentage forced expiratory volume in 1 second with patients with Pseudomonas aeruginosa infection. Outcome measures were survival time, deaths from "cepacia syndrome", rate of decline in spirometry and body mass index (BMI), and treatment requirements. RESULTS: Forty nine patients had an initial infection with either B multivorans (n = 16) or B cenocepacia (n = 33); 8/16 and 31/33, respectively, developed chronic infection (p<0.001). Deaths from "cepacia syndrome" occurred in both BCC groups. Patients with B cenocepacia infection had a shorter survival than patients with P aeruginosa infection (p = 0.01). There was no difference in survival between CF patients infected with B multivorans and P aeruginosa. There were no observed differences in changes in spirometry and BMI or treatment requirements between the BCC groups and respective controls. CONCLUSION: In CF, the genomovar status of BCC may influence both the likelihood of progression from initial to chronic infection and the overall survival of the patients.
Authors: E Mahenthiralingam; T Coenye; J W Chung; D P Speert; J R Govan; P Taylor; P Vandamme Journal: J Clin Microbiol Date: 2000-02 Impact factor: 5.948
Authors: J R Govan; P H Brown; J Maddison; C J Doherty; J W Nelson; M Dodd; A P Greening; A K Webb Journal: Lancet Date: 1993-07-03 Impact factor: 79.321
Authors: D D Frangolias; E Mahenthiralingam; S Rae; J M Raboud; A G Davidson; R Wittmann; P G Wilcox Journal: Am J Respir Crit Care Med Date: 1999-11 Impact factor: 21.405
Authors: E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme Journal: J Clin Microbiol Date: 2000-09 Impact factor: 5.948
Authors: P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan Journal: Int J Syst Bacteriol Date: 1997-10
Authors: Benjamin T Kopp; Basant A Abdulrahman; Arwa A Khweek; Surender B Kumar; Anwari Akhter; Richard Montione; Mia F Tazi; Kyle Caution; Karen McCoy; Amal O Amer Journal: Biochem Biophys Res Commun Date: 2012-06-20 Impact factor: 3.575
Authors: William G Flight; Ann Smith; Christopher Paisey; Julian R Marchesi; Matthew J Bull; Phillip J Norville; Ken J Mutton; A Kevin Webb; Rowland J Bright-Thomas; Andrew M Jones; Eshwar Mahenthiralingam Journal: J Clin Microbiol Date: 2015-04-15 Impact factor: 5.948
Authors: Kay A Ramsay; Claire A Butler; Stuart Paynter; Robert S Ware; Timothy J Kidd; Claire E Wainwright; Scott C Bell Journal: J Clin Microbiol Date: 2013-09-18 Impact factor: 5.948